RESPIRATORY THERAPEUTICS AND DEVICES MARKETS
(SAMPLE COPY, NOT FOR RESALE)
TABLE OF CONTENTS

1. Overview 8
   1.1 Statement of Report 8
   1.2 About This Report 8
   1.3 Scope of the Report 9
   1.4 Objectives 11
   1.5 Methodology 12
   1.6 Executive summary 13

2. Respiratory Epidemiological Analysis 21
   2.1 COPD 21
      2.1.1 Background and Pathogenesis 25
      2.1.2 Diagnosis and Staging of COPD 28
      2.1.3 COPD Management 29
      2.1.4 COPD Therapeutics 30
         2.1.4.1 Bronchodilators 30
         2.1.4.2 Beta Agonists 30
         2.1.4.3 Anticholinergics 30
         2.1.4.4 Methylxanthines 30
         2.1.4.5 Corticosteroids 31
      2.1.5 Inhaled Medication Delivery Systems 31
      2.1.6 Economic Cost of COPD 32
   2.2 Asthma 34
      2.2.1 Background and Pathogenesis 39
      2.2.2 Molecular Mechanisms of Asthma 40
      2.2.3 Risk Factors Related to Disease 41
      2.2.4 Exacerbating Factors 41
         2.2.4.1 Allergens 42
         2.2.4.2 Infections 42
         2.2.4.3 Exercise 42
         2.2.4.4 Nonsteroidal Anti-inflammatory Drugs 42
      2.2.5 Asthma Management and Prevention 43
      2.2.6 Asthma Treatment 43
         2.2.6.1 Short-Acting Beta-Agonists 43
         2.2.6.2 Inhaled Corticosteroids 44
         2.2.6.3 Long-Acting Beta-Agonists 44
         2.2.6.4 Oral Glucocorticosteroids 44
      2.2.7 Single Maintenance and Reliever Therapy (SMART) 44
      2.2.8 Immunotherapy for Asthma 45
      2.2.9 Economic Burden of Asthma 45
   2.3 Upper Respiratory Infections 48
      2.3.1 Allergic Rhinitis 48
      2.3.2 Influenza 49
      2.3.3 Respiratory Syncytial Virus 53
      2.3.4 Sinusitis 53
      2.3.5 Pharyngitis/Tonsillitis 54
      2.3.6 Economic Cost of Upper Respiratory Infections 55
   2.4 Cystic Fibrosis 56
      2.4.1 Background and Pathophysiology 58
      2.4.2 Cystic Fibrosis Treatment and Management 60
      2.4.3 New therapies for Cystic Fibrosis 62
2.4.3.1 Gene Therapy for Cystic Fibrosis 63
2.4.3.2 Novel CFTR Modulation 64
2.4.3.3 Anti-inflammatory Cystic Fibrosis Therapy 64
2.4.3.4 Anti-infective Agents in Cystic Fibrosis 65
2.4.3.5 Mucoactive Agents in Cystic Fibrosis 65
2.4.4 Economic Burden of CF 65

3. Major Drug Classes in Treating Respiratory Diseases 67
3.1 Leukotriene Inhibitors 67
3.2 Corticosteroids 68
3.3 Beta-2 (Adrenoreceptor) Agonists 69
3.4 Antihistamines 69
3.5 Monoclonal Antibodies 70

4. Global Market Analysis—Leading Therapeutics and Players 71
4.1 COPD Market Analysis 71
4.1.1 Leading Therapeutics in COPD market 74
4.1.2 Main Players in COPD 75
4.1.3 COPD Market Forecast 78
4.1.3.1 Revenue Forecasts 78
4.1.3.2 Market Drivers 78
4.1.3.3 Market Restraints 78
4.1.4 Market and Technology Trends 79
4.2 Asthma Market Analysis 79
4.2.1 Leading Therapeutics in Asthma 80
4.2.2 Main Players in Asthma 82
4.2.3 New Asthma Therapeutics 83
4.2.4 Asthma Market Forecast 83
4.2.4.1 Revenue Forecasts 83
4.2.4.2 Market Drivers 84
4.2.4.3 Market Restraints 84
4.2.4.4 Market and Technology Trends 84
4.3 Cystic Fibrosis Market Analysis 85
4.3.1 Leading Therapeutics in Cystic Fibrosis 86
4.3.2 Main Players in Cystic Fibrosis 86
4.3.3 Cystic Fibrosis Market Forecast 87
4.3.3.1 Market Drivers 87
4.3.3.2 Market Restraints 87
4.3.3.3 Market and Technology Trends 87
4.4 Respiratory Syncytial Virus Market Analysis 88
4.4.1 Immunoprophylactic Antibody Market Analysis 90
4.4.2 RSV Vaccine Market 90
4.4.3 RSV Antiviral Market Analysis 90
4.5 Allergic Rhinitis Market Analysis 91
4.5.1 Intranasal Corticosteroid Market 91
4.5.2 Antihistamine Market 92
4.5.3 Over-the-Counter Market 92

5. The Respiratory Pipeline—Analysis of Future Therapeutics 93
5.1 The COPD Market 93
5.1.2 Upcoming COPD Therapeutics 93
5.1.2.1 Phosphodiesterase Inhibitors 94
5.1.2.2 Long-Acting Muscarinic Antagonists 95
5.1.2.3 Long-Acting Beta-Agonists 95
5.1.2.4 Mediator Antagonists 95
5.1.2.5 Leukotriene-B4 Inhibitors 96
5.1.2.6 Chemokine Inhibitors 96
5.2 The Asthma Market 97
5.2.1 Upcoming Asthma Therapeutics 98
5.2.1.1 Bronchodilators 98
5.2.1.2 Corticosteroids 98
5.2.1.3 Cytokine Blockers 99
5.2.1.4 Chemokine Antagonists 99
5.2.1.5 Phosphodiesterase Inhibitors 99
5.2.1.6 Kinase Inhibitors 100
5.2.1.7 Mast Cell Inhibitors 100
5.3 The Cystic Fibrosis Market 101
5.3.1 Upcoming Cystic Fibrosis Therapeutics 102
5.4 Influenza Market 103
5.4.1 Upcoming Influenza Treatments 108
5.4.1.1 Adjuvant Technology 108
5.4.1.2 Improving Manufacturing Techniques 108
5.5 The Respiratory Care Devices Market 110
6.1 Aerosol Generation and Efficient Delivery 110
6.2 Medication Delivery Systems 111
6.3 Nebulizers 112
6.3.1 Nebulizer Market Grows 114
6.3.2 Portable, Compact and Noiseless Nebulizers—Gain Popularity 115
6.4 Dry Powder Inhalers 115
6.5 Pressurized Metered-Dose Inhalers 116
6.6 Ventilators Market 117
6.7 Pulmonary Function Testing Equipment—Spirometry 118
6.8 Sleep Apnea Therapeutic Devices Market—CPAP/Bi-level Devices 119
6.8.1 CPAP Equipment Gain Popularity in the Pre-Hospital Setting 121
6.9 Humidifiers 121
6.10 Oxygen Equipment 122
6.11 Reusable Resuscitators 123
7. Respiratory Care Industry Market Analysis 128
7.1 Medication Delivery System Market Analysis 128
7.2 Medical Ventilator Market analysis 130
7.3 Pulmonary Function Test Market Analysis 131
7.4 Continuous Positive Airway Pressure Therapy Market Analysis 132
7.5 Humidifier Market Analysis 134
7.6 Long Term Oxygen Treatment Market Analysis 135
7.7 Reimbursement Cuts Negatively Affect the Respiratory Market 135
7.8 Growing Incidence Rates for Respiratory Disorders to Propel Demand for Respiratory Devices 137
7.9 Availability of Reimbursement in the U.S. to Drive Sales of Respiratory Devices 137
7.10 Growth in Home Healthcare to Result in Increased Demand for Respiratory Devices in the Future 137
7.11 Development of Technologically Advanced and User Friendly Systems to Increase Adoption of Respiratory Devices 138
8. SWOT Analysis of the Respiratory Market 141
8.1 Biopharmaceutical Industry—Key Aspects of 2010 141
8.2 Main Drivers for Respiratory Therapeutics 143
8.3 Main Restraints for Respiratory Therapeutic and Device Market 144
8.4 Challenges of Respiratory Therapeutics and Devices Going Forward 146
8.5 An Emerging Market: Focus on Chinese Health Biotechnology Market 148
8.6 Summary of Market Strengths, Weaknesses, Opportunities and Threats 150
9. Major Players in the Respiratory Market 152
  9.1 Aerogen 152
  9.2 Altana AG 152
  9.3 Aradigm 152
  9.4 AstraZeneca 152
  9.5 Boehringer Ingelheim 152
  9.6 CareFusion 153
  9.7 Covidien 153
  9.8 DeVilbiss Healthcare 154
  9.9 Drager 154
  9.10 Fisher & Paykel Healthcare 154
  9.11 GlaxoSmithKline 154
  9.12 Merck & Co. 155
  9.13 Nektar Therapeutics 156
  9.14 Novartis 156
  9.15 Pfizer 157
  9.16 ResMed 158
  9.17 Respironics 158
  9.18 Roche 158
  9.19 Schering-Plough 158
  9.20 Sepracor 158

INDEX OF FIGURES

Figure 1.1: Smoking Culture Segmentation of the U.S. Population 16
Figure 1.2: Smoking Trends of U.S. Male and Female Population 16
Figure 1.3: Current Smoking Trends in U.S. by Ethnicity 17
Figure 2.1: COPD is the Fourth Main Killer in the U.S., 2006 21
Figure 2.2: COPD Death Rates in the U.S., 1999-2006 22
Figure 2.3: Age-standardized Death Rate for COPD in the U.S., 1999-2006 22
Figure 2.4: Chronic Bronchitis in the Lungs 25
Figure 2.5: Emphysema of the Lungs 26
Figure 2.6: Pulmonary and Systemic Inflammation in Acute COPD Exacerbations 27
Figure 2.7: Management of Patients with Moderate to Severe Exacerbations of COPD 29
Figure 2.8: Economic Impact of COPD 33
Figure 2.9: International Asthma Prevalence Ranking 34
Figure 2.10: Percentage Asthma Prevalence in the U.S. 35
Figure 2.11: Self-reported Lifetime Asthma Prevalence Rate by State in the U.S. 35
Figure 2.12: Self-reported Current Asthma Prevalence Rate by State in the U.S. 36
Figure 2.13: Ratio of Adult Self-reported Current to Lifetime Asthma by State in the U.S. 37
Figure 2.14: Asthma Prevalence by Age, Sex and Race in the U.S. 38
Figure 2.15: Prevalence of Current Asthma among Persons of All Ages in the U.S., 2001-2009 38
Figure 2.16: Prevalence of Current Asthma among Persons of All Ages by Age Group and Sex in the U.S., 2009 39
Figure 2.17: The Epithelial-Mesenchymal Trophic Unit in Asthma 40
Figure 2.18: Stepwise Asthma Treatment 43
Figure 2.19: Economic Burden of Asthma on U.S. Economy, 1992-2010 46
Figure 2.20: Percentage of Diagnostic Tests Used by Healthcare Providers to Diagnose Allergic Rhinitis in Children 48
Figure 2.21: Percentage of Allergic Rhinitis Incidence by Season 49
Figure 2.22: Top Triggers of Allergic Rhinitis in Population 49
Figure 2.23: Percentage of Respiratory Specimens that Tested Positive for Influenza, October 2010 50
Figure 2.24: Geographic Areas with Confirmed Human Cases of H5N1 Avian Influenza since
January 2010  51
Figure 2.25: Number of Reported and Confirmed Cases of Influenza H1N1 Strain Worldwide  52
Figure 2.26: Detailed Structure of the Throat and Pharynx  55
Figure 2.27: Prevalence of Cystic Fibrosis in the U.S. and Europe  57
Figure 2.28: European Prevalence per 10,000 Population of Cystic Fibrosis  58
Figure 2.29: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Structure  59
Figure 2.30: Pathogenesis of Cystic Fibrosis  60
Figure 3.1: Leukotriene Inhibitor Biochemical Pathway  67
Figure 3.2: Corticosteroid Biosynthetic Endogenous Pathway  68
Figure 4.1: Global Pharmaceutical Sales, 2008-2010  71
Figure 4.2: Global Segmentation of Pharmaceutical Sales, 2009 72
Figure 4.3: Percentage of World Market by Geographic Region  72
Figure 4.4: COPD Market Percentage Share by Country Market  73
Figure 4.5: Global Advair Sales by Market, 2010  73
Figure 4.6: Prescription Respiratory World Market Share Differentiated by Disease State  74
Figure 4.7: Worldwide Prevalence of COPD  75
Figure 4.8: Top Blockbuster COPD Therapeutics Global Sales, 2009 76
Figure 4.9: Percentage Market Share of Leading Asthma Pharmaceuticals  80
Figure 4.10: Top Selling Global Asthma Therapeutics  81
Figure 4.11: Global Sales of the Major Players in the Asthma Market  82
Figure 4.12: Cystic Fibrosis Market Forecast, 2010 and 2015  85
Figure 4.13: Potential Patient Pool requiring Respiratory Syncytial Virus Treatment  89
Figure 4.14: Market Dynamics of Main Respiratory Syncytial Virus Therapeutic Agents, 2007-2015  90
Figure 4.15: Global Market Segmentation of Allergic Rhinitis  91
Figure 5.1: Market Share of Specific Therapeutic Classes for COPD, 2002-2007  93
Figure 5.2: Percentage Share of Novel COPD Therapeutics in Clinical Development, 2009 94
Figure 5.3: Mechanisms by which Sensitized Mast Cells can be Inhibited in Asthma  101
Figure 5.4: Major Market Forecast for Cystic Fibrosis Therapeutics, 2010 and 2015  102
Figure 5.5: Prevalence of Cystic Fibrosis Patients in Major Markets  102
Figure 5.6: Global Influenza Market Segmentation, 2007-2014  104
Figure 5.7: Vaccine Sales of Major Pharmaceutical Companies, 2009  104
Figure 5.8: Vaccine Providers and Number of Doses Provided for the U.S. Market: The 2000/2001 to 2008/2009 Influenza Season  105
Figure 5.9: U.S. Vaccine Supply versus Demand for Influenza Seasons 2003/2004 to 2008/2009  106
Figure 5.10: U.S. Population Recommended Receiving the Influenza Vaccine for Seasons 2003/2004 to 2008/2009  106
Figure 5.11: Percentage of Influenza Vaccine Doses Produced that were Distributed for Seasons 2003/2004 to 2008/2009  107
Figure 5.12: Seasonal Influenza Vaccine Market Size and Forecast, 2005/2006 to 2012/2013  107
Figure 6.1: Number of Models of Reusable Resuscitators According to Price Range  124
Figure 6.2: Distribution of Resuscitator Manufacturers Globally  124
Figure 7.1: Market Segmentation for Resmed Sales, 2008-2010  133
Figure 7.2: Percentage Sales by Geographic Region, Fisher & Paykel, 2010  134
Figure 8.1: Number of Approved Biopharmaceuticals in Five Major Markets, 1998-2009  141
Figure 8.2: Projected Replacement Ratios for Large Pharmaceutical Companies 145
Figure 8.3: Total Number of Biopharmaceutical Deals, 2007-2010  146

INDEX OF TABLES

Table 1.1: Key Facts on Chronic Obstructive Pulmonary Disease (COPD)  18
Table 1.2: Key Facts on Asthma  19
Table 2.1: Chronic Obstructive Pulmonary Disease: Estimated Prevalence by Current Occupation and Smoking Status, U.S. Females Age 18 and Over, 1997-2004  23
Table 2.2: Chronic Obstructive Pulmonary Disease: Estimated Prevalence by Current Occupation and Smoking Status, U.S. Males Age 18 and Over, 1997-2004

Table 2.3: COPD Risk Factors Source GOLD

Table 2.4: GOLD Criteria for COPD Staging Based on Post-Bronchodilator FEV1

Table 2.5: Primary indications of COPD Pathogenesis Source GOLD

Table 2.6: Inhaled Corticosteroids Used in the Management of COPD

Table 2.7: Advantages and Disadvantages of Inhaled Delivery Systems for COPD

Table 2.8: Top COPD Inhalers on the Market

Table 2.9: Symptoms of Asthma

Table 2.10: Triggers of Asthma

Table 2.11: Symptoms of an Asthma Attack

Table 2.12: Exacerbating Factors that may lead to an Asthma Attack

Table 2.13: Mechanisms of Allergen Immunotherapy

Table 2.14: Economic Cost of Asthma in the U.S., 2010

Table 2.15: International Costings of Asthma Exacerbations by Disease Severity

Table 2.16: Main Symptoms of Patients with Cystic Fibrosis

Table 2.17: Classifications of Mutations Attributed to Cystic Fibrosis

Table 2.18: Age-specific Presentations of Cystic Fibrosis

Table 2.19: Cystic Fibrosis Disease Management

Table 2.20: Current Respiratory Treatment for Cystic Fibrosis

Table 2.21: Key Novel Cystic Fibrosis Therapeutics

Table 2.22: Drug Development Pipeline Funded by the Cystic Fibrosis Foundation

Table 4.1: Common Beta-2 Agonist Treatments for COPD

Table 4.2: Common Anticholinergic Treatments for COPD

Table 4.3: Common Inhaled Glucocorticosteroid Treatments for COPD

Table 4.4: Combination Short-Acting Beta-2 Agonist and Anticholinergic Treatment for COPD

Table 4.5: Combination Short-Acting Beta-2 Agonist and Inhaled Glucocorticosteroid Treatment for COPD

Table 4.6: Global Market Forecast for the COPD/Asthma Market, 2011-2019

Table 4.7: COPD Market—Market Drivers Ranked in Order of Impact

Table 4.8: COPD Market—Market Restraints Ranked in Order of Impact

Table 4.9: What to Expect from the COPD Market

Table 4.10: Global Market Forecast for the COPD/Asthma Market, 2011-2019

Table 4.11: Asthma Market—Market Drivers Ranked in Order of Impact

Table 4.12: Asthma Market—Market Restraints Ranked in Order of Impact

Table 4.13: What to Expect from the Asthma Market

Table 4.14: Cystic Fibrosis Market—Market Drivers Ranked in Order of Impact

Table 4.15: Cystic Fibrosis Market—Market Restraints Ranked in Order of Impact

Table 4.16: What to Expect from the Cystic Fibrosis Market

Table 4.17: Pipeline Therapeutics against Respiratory Syncytial Virus

Table 5.1: New COPD Mediator Antagonist Therapeutics in Clinical Development

Table 5.2: COPD Pipeline Therapeutics Currently in Development

Table 5.3: Recent Deals between Major Vaccine Pharmaceutical Companies and Domestic Companies in Emerging Markets

Table 5.4: Global Respiratory Devices Market Growth Forecast, 2009-2016

Table 5.5: Factors that Promote Inefficient Aerosol Delivery in Children

Table 5.6: Advantages and Disadvantages of Respiratory Medication Delivery Systems

Table 5.7: Aerosol Therapeutics Available or Under Development

Table 5.8: Inhalation Therapeutics Available for Nebulizer Use

Table 5.9: New Generation Nebulizers

Table 5.10: Dry Powder Inhalers on the Market

Table 5.11: Pressurized Metered Dose Inhalers on the Market

Table 5.12: Mechanisms of Action of Continuous Positive Airway Pressure (CPAP)

Table 5.13: Advantages and Disadvantages of Non-invasive Positive Pressure Ventilation

Table 5.14: CPAP Device Considerations for the Pre-Hospital Setting
Table 6.12: Types of Humidifiers Available on the Market 122
Table 6.13: Challenges to Oxygen Delivery Technology 123
Table 6.14: Resuscitator Manufactures in China and Taiwan 125
Table 6.15: Resuscitator Manufactures in Europe 125
Table 6.16: Resuscitator Manufactures in India 125
Table 6.17: Resuscitator Manufactures in the U.K. 126
Table 6.18: Resuscitator Manufactures in the U.S. 126
Table 6.19: Price Comparison of Reusable Resuscitators on the Market 127
Table 7.1: Key Factors Driving the Respiratory Care Industry 128
Table 7.2: Key Drivers of the Global Ventilator Market 130
Table 7.3: Key Growth Factors in the Sleep Apnea Therapeutic Devices Market 132
Table 7.4: Key Restraints in the Sleep Apnea Therapeutic Devices Market 133
Table 7.5: Economic and Geographic Determinants of Global Reimbursement Cuts 135
Table 7.6: Hospital Costs due to Reimbursement Changes in Healthcare Reform Law 136
Table 7.7: Growing Incidence Rates for Respiratory Disorders 137
Table 8.1: Top Ten Selling Biopharmaceuticals, 2009 142
Table 8.2: Top Ten Biopharmaceutical Drops, 2010 142
Table 8.3: Key Merger and Acquisition Deals, 2010 143
Table 8.4: BioPharmaceutical Therapeutics Facing Patent Expiration in the U.S. 144
Table 8.5: Potential Challenges of Respiratory Therapeutics and Device Market 146
Table 8.6: Ones to Watch—Chinese Biopharmaceutical Companies on the Up 149
Table 8.7: Summary of Strengths, Weaknesses, Opportunities and Threats of Respiratory Market 151
1. Overview

1.1 Statement of Report

In the respiratory therapeutics and devices market, continuing new advancements in the ability to detect and manage respiratory diseases are being made. The respiratory disease space is one of the most profitable sectors of therapeutics, and it is expected to be growing vigorously into the future. This TriMark Publications report analyzes various respiratory therapeutics and devices markets, with special attention paid to therapeutic remedies for chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Also addressed in this study are therapeutics for upper respiratory infections such as: allergic rhinitis, influenza, respiratory syncytial virus, sinusitis, and pharyngitis/tonsillitis. From respiratory devices side, key segments covered include: continuous positive airway pressure (CPAP) devices, ventilators, nebulizers, oxygen concentrators, humidifiers and reusable resuscitators. This review covers the leading market players, the competitive landscape, and the emerging pipeline products in the respiratory therapeutics and devices markets. Specifically, areas examined in this study include: available and developing technologies in the field, the U.S. and global market size for respiratory therapeutic products, and the profiles of companies that are focusing on the respiratory therapeutics and devices market. This review analyzes the size and growth of the therapeutic respiratory disease category, including the factors that influence the various market segments within it. Detailed charts with sales forecasts and market share data for the U.S. and global respiratory therapeutics and devices markets are included.

Also examined are:

- Major drug classes in treating respiratory diseases.
- Leading therapeutics and players.
- The respiratory pipeline and analysis of future therapeutics.
- Respiratory care industry market analysis.
- SWOT analysis of the respiratory market.
- Main drivers for respiratory therapeutics.
- Main restraints for respiratory market.
- Challenges of respiratory therapeutics going forward.
- Emerging market: Focus on Chinese health biotechnology market.
- Summary of market strengths, weaknesses, opportunities and threats.
- Key companies participating in this sector.

This market report analyzes the size and growth of the respiratory therapy market, examining the factors that influence the various market segments and the dollar volume of sales, both in the U.S. and worldwide. The respiratory disease market has been divided into the following parts for examination:

- COPD.
- Asthma.
- Upper respiratory infections such as allergic rhinitis, influenza, respiratory syncytial virus, sinusitis, and pharyngitis/tonsillitis.

This choice of disease states is based upon the available therapeutic advances and the number of companies interested in that segment of the respiratory disease market.

1.2 About This Report

This report includes the following features for each major respiratory disease market:

- Develop business strategies by understanding the trends and developments that are driving the respiratory therapeutics market globally.
- Design and develop your product development, marketing and sales strategies.
• Exploit mergers and acquisitions (M&A) opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Identify key players best positioned to take advantage of the Emerging market opportunities.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• What’s the next being thing in the anesthesia and respiratory devices market landscape?
• Make informed business decisions from the in-depth analysis of the global.
• Respiratory therapeutics market and the factors shaping it.

1.3 Scope of the Report

The goal of this study is to review the market for respiratory disease therapeutics and disease management equipment and supplies. This market analysis answers the following key questions:

• Which companies are utilizing new, cutting-edge therapeutics to develop, validate and market drugs for clinical use in respiratory disease management?
• What are the current impediments to incorporating promising therapeutic entities into clinical practice?
• Which new therapeutics show the most promise for regulatory approval?
• What are the economic challenges to gaining approval? And what kind is best?
• How does regulatory oversight drive approval and adoption of new drugs?
• Which strategic alliances show the greatest synergy in bringing respiratory therapies to the market?
• Which shared technologies are driving the most encouraging development of new respiratory therapeutic methods?
• Estimate the current and future U.S. and global markets for respiratory disease.
• Examine market drivers that have resulted in the global race for new respiratory disease therapeutics.
• Assess market opportunities and the potential market pertaining to the disease indications.
• Discuss product development challenges in relation to regulatory constraints, legislative constraints and technical challenges.
• Understand the impact of current products in medical ventilator market.
• Analyze the need for respiratory management and care devices.
• Analyze the pulmonary function test market.
• Analyze the continuous positive airway pressure therapy market.
• Analyze the humidifier market.
• Analyze the long-term oxygen treatment market.
• Provide insight into the respiratory products pipeline and the companies that strive to bring these products to the market in the immediate future.
• Evaluate global activity in respiratory care with specific contributions from the top-ranking five countries: U.S., Japan, Germany, U.K. and China.
• Analyze the segments in therapeutics for major diseases like COPD, asthma, and cystic fibrosis.
• Gain insight into the current applications of major drug classes in treating respiratory diseases.
• Explore drug discovery efforts in relation to respiratory diseases.
• Analyze the usual hurdles new therapeutic products are encountering to reach the market and the right path to the market for these products.
• Review the current licensing, investing and partnering activities in the respiratory disease sector.
• Assess business models and requirements for a successful pharmaceutical industry.
• Identify the key players in the respiratory disease sector.

Key questions answered in this study are:

• What are the products that come under the phrase “respiratory therapies”?
• What disease conditions offer the greatest potential for respiratory therapy technology platforms?
• What is the current global market for respiratory therapies?
• How much of clinical development activities are taking place globally in respiratory therapies sector?
• How many companies are involved in the development of respiratory therapy products?
• How many patents have been issued for respiratory therapies products in infectious disease?
• What market drivers are responsible for the global growth in therapy and management of respiratory disease?
• What regulatory and technical challenges are being confronted by the respiratory therapies industry?
• What are the current promising developments in respiratory therapies disease sector?
• What is the latest position of the clinical studies and product pipeline in the respiratory therapies disease sector?
• How long it will take for the respiratory therapy technology platforms to become the standard of clinical practice to replace older and less efficacious medicines?
• How much of venture capital funding was invested into the respiratory therapies sector?
• What is the potential population in the U.S. for respiratory disease diagnosis?
• What are the top ten respiratory therapies products available in the market place?
• How many companies are involved in the development of respiratory therapies products?
• How many firms concentrate on asthma products?
• Which firms are involved in the development of COPD products?
• Which companies are focused on the development of cystic fibrosis products?
• Which companies are focusing on upper respiratory therapies products?
• Which companies are associated with developing respiratory care management products?
• What are the different business models suitable for the different types of respiratory therapies products?
• What are the requirements for the commercial manufacturing of respiratory therapies products?
• What are the different funding sources in the U.S. for the development of respiratory therapies products?

This report contains:

• Current market opportunities for respiratory therapy products.
• Product development challenges confronted by the respiratory therapies industry.
• A brief discussion on the need for respiratory therapies and the advantages over the conventional clinical approaches.
• The future direction of the emerging respiratory therapies products.
• The overall picture of pipeline products in respiratory therapies sector and the companies involved.
• A note on the projected time-line for respiratory therapies products.
• A market projection for global respiratory therapies products.
• Listing and explaining the most popular respiratory therapies products in the market.
• Presentation of the global picture of the respiratory therapy products market with particular reference to the leading countries, such as U.S., Japan, Germany, U.K. and China.
• Number of firms engaged in respiratory therapies products.

This examination surveys most of the pharmaceutical companies known to be currently marketing, manufacturing or developing products for the respiratory market for both therapy and disease management, in both the U.S. and the world. Each company is discussed in depth, with sections on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position. The U.S. is the focus of this report. Primary attention is paid to leading players and therapies in the COPD, asthma, cystic fibrosis, and upper respiratory disease segments.
1.4 Objectives

The main objectives of this analysis are in identifying viable technology drivers through a comprehensive look at platform technologies for respiratory disease management, including the respiratory pipeline and analysis of future therapeutics:

**The COPD Market**
- Upcoming COPD therapeutics.
- Phosphodiesterase inhibitors.
- Long acting muscarinic antagonists.
- Long-acting beta-agonists.
- Mediator antagonists.
- Leukotriene-B4 inhibitors.
- Chemokine inhibitors.

**The Asthma Market**
- Upcoming asthma therapeutics.
- Bronchodilators.
- Corticosteroids.
- Cytokine blockers.
- Chemokine antagonists.
- Phosphodiesterase inhibitors.
- Kinase inhibitors.
- Mast cell inhibitors.

**The Cystic Fibrosis Market**
- Upcoming cystic fibrosis therapeutics.
- New therapies for CF.
- Gene therapy for cystic fibrosis.
- Novel CFTR modulation.
- Anti-inflammatory cystic fibrosis therapy.
- Anti-infective agents in cystic fibrosis.
- Mucoactive agents in cystic fibrosis.

**The Influenza Market**
- Upcoming influenza treatments.
- Discovering feasible market opportunities by identifying high-growth applications in different clinical disease areas.
- Focusing on global industry development through an in-depth analysis of the major world markets for respiratory disease management, including growth forecasts.

The emphasis in this report is on the use of therapeutic products for respiratory disease management. The reader should consult other TriMark Publications reports (see http://www.trimarkpublications.com) for detailed discussions of important individual market segments related to the medical devices and supplies markets. For example, TriMark has separate reports on *Cardiac Rhythm Management Devices World Markets, Disposable Medical Supplies Markets, Disposable Syringe Markets, Home Medical Testing Devices, Orthopedics Markets, Patient Monitoring Markets, Plastic Surgery Markets* and *Sleep Disorders* focused on insomnia, sleep apnea, restless leg syndrome, bruxism, narcolepsy and sleepwalking.
1.5 Methodology

The author of this report holds a Ph.D. in respiratory medicine/immunology from the Royal College Surgeons of Ireland and has completed post-doctoral studies and lecturing in Trinity College Dublin and University College Cork. The author has many decades of experience in scientific writing and as a medical industry analyst. As an expert in the respiratory disease field, she has managed many research programs, and has held senior scientist positions in academia. The author has significant experience in international scientific writing, and has peer reviewed cutting edge research.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates’ databases and from TriMark’s private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with, and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources
TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources
TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report, Research and Data Acquisition Structure
The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.

- Formulating a study outline with the assigned writer, including important items, as follows:
  - Market and product segment grouping, and evaluating their relative significance.
  - Key competitors’ evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
  - End-user research to evaluate analytical significance in market estimation.
  - Supply chain research and analysis to identify any factors affecting the market.
  - New technology platforms and cutting-edge applications.
• Identifying the key technology and market trends that drive or affect these markets.

• Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.

• Completing a confirmatory primary research assessment of the report’s findings with the assistance of expert panel partners from the industry being analyzed.

1.6 Executive summary

Specific Objectives of this report are to:

• Examine the current and future respiratory therapeutic and device market and provide a critical analysis of its advantages and disadvantages.

• Give a detailed account of the current respiratory disorders that are the main players in this market and provide descriptions of first line therapies, devices required and future therapeutics.

• Provide a detailed understanding of the principles of respiratory therapeutics.

• Evaluate the global economic impact of current therapeutics, patient expirations and future potentials.

• Therapeutics with potential currently in clinical trials or pipeline.

• Present market sales figures, identifying submarket figures and predicting the future of the respiratory therapeutic and device market.

• Outlining the markets strengths, weaknesses, opportunities and threats.

• Investigate the Chinese market with respect to the overall pharmaceutical business and more specifically the respiratory industry.

The respiratory therapeutic and device market is highly competitive and is compiled of a large range of drugs and devices that cater for patients with both acute and chronic symptoms. Currently, the total market is generating high revenues and this has the potential to increase as respiratory illness prevalence increases globally. Penetration into Emerging markets will also see an increase in revenue in the future.

Global pharmaceutical sales in 2009 were estimated at $738 billion, a significant increase from $577 billion in the previous year. The U.S. market dominated with $295 billion in sales, Europe claimed $206 billion and the rest of the world commanded $236 billion. Respiratory therapeutics was the sixth most competitive market and was values at $58.4 billion in 2009 with a growth figure of 5.4%. Respiratory market growth was driven by sales in asthma and COPD therapeutics which made up over $20 billion of this market. Allergic rhinitis had the second largest sales figure with just over $12 billion globally.

The main submarkets of the respiratory therapeutic and device market are COPD, asthma and allergic rhinitis. Globally there are over 510 million people living with COPD or asthma. The COPD/asthma market is predicted to reach international sales of $24.2 billion by 2019 with a compound annual growth rate (CAGR) of 1.2% (2009-2019). Over the last number of years the annual growth rate has been higher at 10.4% in the major markets including the U.S. and was driven by intense marketing of combination therapeutics. These agents continue to dominate the market and in combination therapy of inhaled corticosteroids and long-acting beta-agonists (LABAs) demanded a market share of 70% globally.

The main respiratory therapeutics on the market today are:

• Combination therapies (Advair/Seretide, Symbicort and Combivent).

• Corticosteroids (Pulmicort, Nasonex/Asmanex and Flovent/Flixotide).

• Leukotriene inhibitors (Singulair).

• Beta-2 agonists (Xopenex, Salamol and Ventolin).

• Antihistamines (Clarinex/Aerius, Allegra/Telfast and Zyrtek).

• Monoclonal Antibodies (Synagis and Xolair).
• Anticholinergics (Spiriva).

In the short-term, however, it is predicted that between now and 2015, the market will be unstable. This is mainly due to important patents expiring, and the wait for newer therapies to enter the marketplace. The coming years will also see competition for dominance within key areas such as asthma and COPD. New therapies for treatment of cystic fibrosis are critical in increasing its dominance in the respiratory field.

Respiratory diseases are increasing in prevalence globally. According a National Health Interview Survey in 2009 that was performed by the Department of Health and Human Services, Centers for Disease Control and Prevention and the National Center for Health Statistics:

• 2% of U.S. adults have been diagnosed with emphysema.
• 13% of U.S. adults have been diagnosed asthma and 8% currently have asthma.
• 13% of U.S. adults have been diagnosed with sinusitis.
• 4% of U.S. adults have been diagnosed with chronic bronchitis.

The survey revealed that there is also a gender imbalance when it comes to respiratory disorders:

• Women are more likely to be diagnosed with asthma, sinusitis and chronic bronchitis than men.
• Men are more likely to be diagnosed with emphysema, than women.

There is also a differential prevalence of respiratory diseases amongst certain ethnic groups in the U.S.:

• Asian U.S. adults are less likely to be diagnosed with asthma, chronic bronchitis or sinusitis than Blacks or Whites.
• Hispanic adults have lower incidences of asthma and sinusitis than non-Hispanic White or non-Hispanic Black adults.
• Hispanic adults are less likely to be diagnosed with emphysema or chronic bronchitis than non-Hispanic Whites.

Socio-economic background was also found to play a role in the National Health Survey with respect to respiratory diseases.

• Adults with a University degree are less likely to be diagnosed with chronic bronchitis or emphysema.
• Lower income adults tend to have higher rates of asthma, emphysema and chronic bronchitis.

Smoking is a major contributing factor to developing respiratory illnesses such as COPD and is known to exacerbate conditions such as asthma. There has been a significant increase in COPD cases in developing countries and this is associated with a more prevalent smoking culture. Meanwhile in the developed world it is estimated that up to 90% of COPD deaths are attributed to smoking.

• 21% of U.S. adults are current cigarette smokers.
• 21% of U.S. adults were former smokers.
• 58% of U.S. adults have never smoked.